The Motley Fool: An inside look at Amgen’s fall

Shares of Amgen started crashing in early November and didn’t improve when the company released data from a Phase 2 clinical trial for its weight-loss candidate MariTide. That plunge has set the stock up for some serious potential gains in 2025. Amgen’s stock price fell further because its monthly injectable drug helped people lose (on average) only around 20% of their body weight after 52 weeks — as opposed to the 25% that analysts were expecting. Too many investment decisions these days are based on whether something beats expectations —...